Esperion Therapeutics (ESPR) Change in Receivables (2020 - 2026)

Esperion Therapeutics has reported Change in Receivables for 7 years, with the latest figure at -$7.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 780.38% year-over-year to -$7.8 million; the trailing twelve-month figure through Mar 2026 stood at $51.1 million (up 91.36% YoY), and the FY2025 full-year result was $60.0 million, up 89.74% from the prior year.
• Change in Receivables for Q1 2026 stood at -$7.8 million, down from $21.2 million in the prior quarter.
• The five-year high for Change in Receivables was $26.5 million in Q2 2025, with the low at -$7.8 million in Q1 2026.
• Historically, Change in Receivables has averaged $6.4 million across 5 years, with a median of $4.4 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 2631.25% — and 2026, when it slumped 780.38%.
• Esperion Therapeutics' Change in Receivables stood at $2.2 million in 2022, then soared by 162.1% to $5.9 million in 2023, then soared by 109.81% to $12.3 million in 2024, then jumped by 72.19% to $21.2 million in 2025, then tumbled by 136.95% to -$7.8 million in 2026.
• The last three Change in Receivables figures came in at -$7.8 million (Q1 2026), $21.2 million (Q4 2025), and $11.2 million (Q3 2025), per Business Quant data.